albert bourla

AI models already exceed current utilization in drug discovery (target identification, molecule synthesis, clinical trial design) and manufacturing/commercial, but the bottleneck is organizational transformation — Pfizer is decentralizing AI accountability to business unit leaders with mandatory AI literacy training to close the technology overhang.

China's 14th five-year plan executed systematically: built competent FDA, strong IP protection, and fast judiciary — now 8 of top 10 universities in Nature Index are Chinese. They lead in early-stage oncology/obesity with 10x company density. Bourla argues US should focus 80% effort on out-innovating China (regulatory reform, NIH funding, drug pricing policy) rather than slowing China down.

Pfizer's MyThera acquisition targets monthly GLP-1 dosing advantage over weekly Lilly/Novo products, leveraging Pfizer's primary care trial infrastructure, commercial powerhouse, and manufacturing network that can produce at lower cost and higher speed — critical as China enters with structural cost advantages.

Pfizer doubled phase 2 success rates (20% to 50%+) and achieved 95% regulatory success by merging early/late R&D under single leadership, eliminating handover friction, and shifting portfolio selection from 'develop everything with positive data' to commercially focused bets — a governance/culture fix achievable in months not years.

Bourla expects AI plus biology advances to radically change standards of care by 2030, disrupting research, manufacturing, commercial, hospitals, physicians, and regulators — the scale of disruption will determine which pharma companies survive as winners.